K2X Technology & Life Science, Inc.

Equities

KBPH

US5015722003

Financial & Commodity Market Operators

Market Closed - OTC Markets Other stock markets 03:30:56 2022-08-22 pm EDT			5-day change	1st Jan Change
1 ^USD	-45.65%		-.--%	-.--%

2023	FluidAI Medical announced that it has received CAD 15 million in funding from a group of investors	CI
2023	Infinidome Ltd. announced that it has received $9 million in funding from Hanwha Aerospace Co., Ltd., Next Gear Ventures, Honeywell Ventures, VentureIsrael, Kyto Technology and Life Science, Inc., Aston Capital Management and another investor	CI

Astrocyte Pharmaceuticals Inc. announced that it has received $7.522677 million in funding from CR Ventures, DeepWork Capital, Trend Investment Group, Kyto Technology and Life Science, Inc. and other investors

December 09, 2020

On December 10, 2020, Astrocyte Pharmaceuticals Inc. closed the transaction. The company issued 19,615,846 shares for proceeds of $7,522,677 pursuant to Regulation D. The company received $6,000,000 led by Boston Harbor Angels, and included participation 70 investors including DeepWork Capital, CR Ventures, Trend Investment Group, Dreamers Startup Ventures, Zhi Gao Holdings, Kyto Technology and Life Science, Inc. (OTCPK:KBPH), Life Science Angels, Mass Medical Angels, Mid Atlantic Bio Angels, SideCar Angels, and others.

Latest news about K2X Technology & Life Science, Inc.

FluidAI Medical announced that it has received CAD 15 million in funding from a group of investors	23-10-09	CI
Infinidome Ltd. announced that it has received $9 million in funding from Hanwha Aerospace Co., Ltd., Next Gear Ventures, Honeywell Ventures, VentureIsrael, Kyto Technology and Life Science, Inc., Aston Capital Management and another investor	23-04-23	CI
Mrinq Technologies LLP announced that it has received $2.5 million in funding from a group of investors	22-11-09	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-22	CI
Kyto Technology and Life Science, Inc. announced that it has received $2.620875 million in funding	22-02-03	CI
Rhaeos, Inc. announced that it has received $2.2 million in funding from a group of investors	21-12-22	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-18	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021	21-10-01	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.21 million in funding	21-08-31	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.3 million in funding	21-08-16	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.135 million in funding	21-08-12	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.703 million in funding	21-08-11	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2021	21-08-10	CI
Kyto Technology and Life Science, Inc. Auditor Raises 'Going Concern' Doubt	21-08-09	CI
Single Pass Inc. announced that it has received funding from Kyto Technology and Life Science, Inc., and another investor	21-07-08	CI
AOA Inc. announced that it has received $2.5 million in funding from a group of investors	21-06-27	CI
Kyto Technology and Life Science, Inc. Announces Resignation of Georges Benarroch from the Board of Directors	21-04-12	CI
AOA Inc. announced that it expects to receive $2.5 million in funding	21-02-25	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-16	CI
Kyto Technology and Life Science, Inc. Announces Board Changes	21-01-14	CI
Astrocyte Pharmaceuticals Inc. announced that it has received $7.522677 million in funding from CR Ventures, DeepWork Capital, Trend Investment Group, Kyto Technology and Life Science, Inc. and other investors	20-12-09	CI
Astrocyte Pharmaceuticals Inc. announced that it expects to receive $9.831429 million	20-11-19	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-16	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	20-08-04	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	20-06-30	CI

Chart K2X Technology & Life Science, Inc.

Duration

Period

Chart K2X Technology & Life Science, Inc.

More charts

Company Profile

Kyto Technology and Life Science, Inc. is an investment company focused on creating an exchange-traded fund (ETF)-like vehicle of diversified and thoroughly vetted start-ups thus defining an entirely new non-correlated asset class. The Companyâs portfolio includes AbFero Pharmaceuticals Inc., Achelios Therapeutics, Inc., Altis Biosystems, AmplifiDX, AOA Inc., Astrocyte Pharmaceuticals Inc. and other.

Sector

Financial & Commodity Market Operators

More about the company

Sector Other Financial & Commodity Market Operators

	1st Jan change	Capi.
K2X TECHNOLOGY & LIFE SCIENCE, INC.	-.--%	16.33M
INTERCONTINENTAL EXCHANGE, INC.	+3.86%	76.7B
LONDON STOCK EXCHANGE PLC	-1.01%	61.89B
DEUTSCHE BÖRSE AG	+0.19%	37.32B
NASDAQ, INC.	+3.04%	35.11B
B3 S.A. - BRASIL, BOLSA, BALCÃO	-19.79%	12.84B
EURONEXT N.V.	+10.55%	9.54B
MARKETAXESS HOLDINGS INC.	-30.95%	7.55B
TMX GROUP LIMITED	+14.07%	7.46B
SINGAPORE EXCHANGE LIMITED	-7.02%	7.31B

Other Financial & Commodity Market Operators